NCT05924815View on ClinicalTrials.gov

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2023

Conditions
Healthy Participants
Interventions
DRUG

Aficamten

Oral Tablet

DRUG

Aficamten-matching Placebo

Oral Tablet

DRUG

Moxifloxacin

Oral Tablet

Trial Locations (1)

85283

Celerion, Inc 2420, Tempe

Sponsors

Lead Sponsor

Cytokinetics
All Listed Sponsors
lead

Cytokinetics

INDUSTRY

NCT05924815 - Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval | Biotech Hunter | Biotech Hunter